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Abstract Inﬂuenza virus types A and B cause yearly
outbreaks of respiratory tract infections in all age
groups including children and adolescents. Complica-
tions, such as high fever, febrile convulsions, secondary
bacterial infections and myositis frequently lead to
hospitalisation. Safe and eﬀective split, subunit and
virosome vaccines are available from 6 months of age
onwards. Most European countries do have guidelines
for the use of inﬂuenza vaccines and current strategies
primarily aim at decreasing the burden of inﬂuenza
disease in certain, heterogeneously deﬁned high risk
groups. Conclusion: Unfortunately, compliance of many
physicians and patients with immunisation recommen-
dations is rather poor and several barriers to immuni-
sation have been identiﬁed. These deserve our speciﬁc
attention in the future. Recently, neuraminidase inhibi-
tors with curative and preventive eﬃcacy against inﬂu-
enza virus types A and B have become available. They
serve as second line weapons for inﬂuenza prophylaxis
under speciﬁc circumstances.
Keywords Immunization Æ Inﬂuenza Æ Neuraminidase
inhibitors Æ Prevention Æ Review
Abbreviations CAIV-T cold-adapted trivalent inﬂuenza
vaccine Æ HA haemagglutinin Æ NA neuraminidase Æ
NI neuraminidase inhibitor Æ RSV respiratory syncytial
virus
Introduction
Although immunisation against inﬂuenza has been rec-
ommended for patients with underlying chronic diseases
for several decades in Europe and other parts of the
world, vaccine up-take in risk groups has remained low
[9, 25,39]. This is probably due to several immunisation
barriers which have been identiﬁed among physicians
and patients [5, 6, 23, 58,59]. Most importantly, mis-
conceptions on the true burden of disease and its com-
plications and lack of awareness of the beneﬁts of
inﬂuenza prevention can be blamed for this unfortunate
state of aﬀairs [23, 40, 55,62].
Traditionally, inﬂuenza has been considered a serious
medical problem in elderly people whereas its signiﬁcant
impact on young infants, children and adolescents has,
until recently, been widely neglected [14]. Here, I will
brieﬂy review the current knowledge on epidemiology
and clinical characteristics of inﬂuenza in the paediatric
age group. Eﬃcient ways of prophylaxis, i.e. by immu-
nisation and use of neuraminidase inhibitors (NIs) will
be discussed with a speciﬁc focus on the situation in
Europe. Moreover, potential interventions to improve
vaccine uptake in the future and desired new aspects in
the ﬁeld of vaccine development will be highlighted. The
goal of this update is to provide facts which may help to
better implement the existing recommendations for
inﬂuenza immunisation.
Epidemiology and clinical characteristics
Inﬂuenza viruses (orthomyxoviridae) can be divided into
three major antigenic groups named types A, B and C.
While natural infections with viral types B and C are
restricted to human beings, type A infections also occur
in birds, pigs and horses [39]. Type A viruses can be
further subtyped according to genetic variability of their
major virulence factors, i.e. haemagglutinin (HA) (des-
ignated H1-H15) and neuraminidase (NA) (N1-N9)
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antigens (Fig. 1) [39]. Point mutations (determined as
antigenic drifts) which seem to occur by selective pres-
sure, lead to antigenic changes within speciﬁc inﬂuenza
virus A and B subtypes. They are responsible for yearly
inﬂuenza epidemics, where type A and B viruses fre-
quently co-circulate. In contrast, major antigenic chan-
ges can take place by means of re-assortment between
gene segments when diﬀerent human and animal inﬂu-
enza virus subtype A strains happen to infect a host at
the same time (Fig. 2), as has been shown experimentally
[56]. This results in an antigenic shift to a completely
new subtype (e.g. from H1N1 to H2N3; Fig. 2) and can
lead to pandemics, the last of which occurred in 1977
[25]. Since then, virus subtypes A/H1N1, A/H2N3 and B
have been most prevalent. Inﬂuenza type C viruses
occasionally cause local outbreaks. Their potential for
epidemics is limited and they therefore play only a minor
clinical role [14, 25, 39].
In the Northern hemisphere, outbreaks of inﬂuenza
A and B occur during the cold season with peaks usually
between December and February. Unfortunately, from
an epidemiological and clinical point of view, other
viruses such as respiratory syncytial virus (RSV) and
parainﬂuenza virus also cause frequent respiratory
infections in children with highest incidence rates during
the winter season. Therefore, these infections frequently
overlap with the inﬂuenza peak and this has complicated
our appreciation of the true burden of inﬂuenza in the
paediatric age group in the past. Fortunately, new
diagnostic tools (such as PCR and rapid antigen tests
applied to nasopharyngeal specimens) and increasing
use of culture techniques have recently provided us with
a much clearer picture of the aetiological role of inﬂu-
enza viruses in acute viral respiratory infections in chil-
dren [42,57]. In a study from Finland, 683 children
hospitalised in one university hospital were diagnosed
with inﬂuenza between 1980 and 1999 [42]. Median age
of patients with inﬂuenza A ( n =544) was 2.0 years
compared to 4.2 years in those with inﬂuenza B
(n =139). Of these patients, 60% were boys and the vast
majority (75%) were previously healthy.
In a regional study from Northern Germany per-
formed between 1996 and 2001, nasopharyngeal speci-
mens of hospitalised children up to 16 years of age with
respiratory infections were analysed by multiplex PCR
[57]. Similar to the observations in Finland, children
with inﬂuenza A ( n=122) had a median age of 2.1 years
compared to 2.6 years in those with inﬂuenza B (n=14).
Incidences (per 100,000 children per year) were 53, 16
and 165 for inﬂuenza A, inﬂuenza B and RSV, respec-
tively. The highest incidence rates for all three virus
infections were recorded in children 0–5 years of age
(123, 30 and 453, respectively) with peaks in the 1st
(RSV: 1563) and 2nd years of life (inﬂuenza A: 161).
Although absolute numbers of cases were comparatively
small, as in Finland, most of the children hospitalised
for inﬂuenza were previously healthy (79%). Neverthe-
less, relative risks for hospitalisation due to inﬂuenza A
were signiﬁcantly increased for children with asthma
(4.1; 95% CI: 1.7–10) and underlying cardiac conditions
(9.8; 95% CI: 4.3–23) [57].
The epidemiological role of inﬂuenza in children is
multi-facetted. On the one hand, the high burden of
disease leads to physician visits, interference with daily
activities such as absence from school, and occasionally
to serious complications. On the other hand, children
have been found to be important multiplicators in the
infectious circle of inﬂuenza. They are regularly aﬀected
early during the start of an epidemic and thus serve as
the source of consequent infections in adult contacts
[13,50].
Classical inﬂuenza is a respiratory infection with
sudden onset of fever, rhinitis, a non-productive, hack-
ing cough, myalgia and malaise, which aﬀects patients at
all ages [9,39]. Interestingly, vomiting and diarrhoea can
be the major symptoms in young infants, especially with
inﬂuenza A virus infection [41,47]. Major complications
of inﬂuenza, which frequently lead to hospitalization in
previously healthy children, include febrile convulsions,
bronchiolitis, pneumonia, croup and myositis [42,57]. In
the Finnish study, otitis media (26% and 19% of chil-
dren with inﬂuenza A and B, respectively), febrile con-
vulsions (12% and 9%), pneumonia (9% and 8%), and
croup (5% and 4%) were the most common complica-
tions [42]. Inﬂuenza virus infections have also been
identiﬁed as a major cause of subsequent secondary
bacterial infections [37,49]. Among these, acute otitis
media, primarily due to Streptocococcus pneumoniae,
plays a major role and best explains the signiﬁcant use of
Fig. 1 Structure of inﬂuenza type A virus with HA and NA as
major virulence factors
Fig. 2 Antigenic shift by re-assortment of diﬀerent inﬂuenza A
virus subtypes leading to a new subtype
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antibiotics in children with inﬂuenza [2,42]. Moreover,
pneumococcal pneumonia and invasive meningococcal
infections have been closely associated with inﬂuenza
virus infections [30,38].
Children and adolescents with underlying chronic
illnesses may suﬀer from signiﬁcant deterioration when
infected with inﬂuenza viruses. In children with intrinsic
asthma, inﬂuenza virus infection can trigger exacerba-
tions [28, 51,52]. It has further been shown that inﬂuenza
is responsible for about 13% of acute exacerbations of
cystic ﬁbrosis during the winter season [46]. Also, chil-
dren with malignant diseases more frequently acquire
inﬂuenza and their illnesses are more severe compared to
healthy age-matched controls [27].
In conclusion, inﬂuenza virus type A and B infections
are a frequent cause of hospitalisation in previously
healthy children during the epidemic season. Children
and adolescents with underlying illnesses are at even
higher risk for hospitalisation due to inﬂuenza when
compared to primary healthy controls. Based on epide-
miological knowledge, preventive measurements in pa-
tients with underlying conditions are highly justiﬁed.
Moreover, given the high burden of disease in primary
healthy children, immunisation strategies beyond the
current target groups at increased risk should be dis-
cussed.
Prevention
Immunisation
Today, several types of inactivated inﬂuenza vaccines
are available: whole-cell, split, subunit and virosomal
(Fig. 3). The selection of virus strains and the NA and
HA antigens to be included in the vaccines is based on
WHO recommendations. Laboratories throughout the
world participate in the WHO global inﬂuenza surveil-
lance system and constantly screen circulating inﬂuenza
viruses for their antigenic constitution. Usually in Feb-
ruary each year, the WHO recommends which three
inﬂuenza strains should be used to formulate the vac-
cines for the coming season in the northern hemisphere.
Reference strains will then be made available for vaccine
manufacturers who have only a few months time for
culture of the viruses, antigen puriﬁcation, toxicity and
immunogenicity analyses, mass production and ﬁnally
distribution of the new vaccine.
The traditional whole virus vaccines demonstrated
favourable immunogenicity results; however, due to
their comparatively high reactogenicity, they are not
licensed for use in children and have also been widely
replaced in other age groups [60]. Compared to whole-
cell vaccines, ‘‘split’’ vaccines (consisting of pieces of
virus as a consequence of disrupting the whole viruses
with detergents) have a much better reactogenicity pro-
ﬁle but also reduced immunogenicity, especially in
young children [17]. Therefore, two doses of vaccine are
recommended in children up to the age of 3 years (or
older in some European countries and the United States)
when immunised against inﬂuenza for the ﬁrst time.
‘‘Subunit’’ vaccines have been further puriﬁed when
compared to split vaccines and mainly contain HA and
NA [29]. Safety and reactogenicity ﬁndings with subunit
vaccines in children are favourable [4,10]. As with split
vaccines, two doses within 4 to 8 weeks are required for
young ﬁrst time vaccinees. Split and subunit vaccines are
widely available throughout Europe and many other
countries worldwide.
A new class of inﬂuenza vaccine has recently been
developed in Switzerland (Inﬂexal V). The vaccine con-
sists of immunopotentiating reconstituted inﬂuenza
virosomes, which are a combination of natural phos-
pholipids, phospholipids deriving from inﬂuenza NA
and HA and phophatidylcholine [15, 16,32]. The vaccine
is trivalent containing three distinct virosome pools. Lot
consistency and stability over prolonged periods of time
(18 months at 5C, 3 months at 25C and 28 days at
37C) have been demonstrated [32]. Clinical experience
with the virosome inﬂuenza vaccine in children has
Fig. 3 Schematic composition of various inﬂuenza vaccines
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recently been summarised [24]. Brieﬂy, in four investi-
gations a total of 127 children 1 to 12 years of age (80
healthy and 43 with cystic ﬁbrosis) received virosome
vaccine and tolerability (n=127) and immunogenicity
(n = 116) were evaluated. When compared to parallel
groups receiving subunit vaccine, the immunogenicity
requirements as deﬁned by the EMEA, the European
registration body, were fulﬁlled at similar rates; speciﬁc
comparative antibody levels have not been published.
Tolerability of virosome vaccine was similar to that of
the subunit vaccine with 54% and 55% of vaccinees
experiencing one or more local adverse events and 44%
and 59% one or more systemic adverse event, respec-
tively. Of note, favourable tolerability and no untoward
immunological eﬀects (CD4+ count and viral load) of
the virosome vaccine have been obtained in a study of 23
HIV-positive children [64]. Inﬂexal V is currently
licensed in 13 European countries: Austria, Denmark,
Finland, Germany, Greece, Italy, the Netherlands,
Portugal, Spain, Sweden, Switzerland (and Liechten-
stein), and the United Kingdom (R. Hoos, Berna
Biotech, Switzerland, personal communication).
Over the last two decades, a live-attenuated, re-as-
sortant, cold-adapted trivalent inﬂuenza vaccine (CAIV-
T) has been developed and studied intensively in all age
groups including young children [14]. It contains struc-
tural genes from attenuated donor strains of types A and
B and re-assorted N and H genes of currently circulating
inﬂuenza viruses. Administration is by the intranasal
route with a large-droplet spray (0.25 ml per nostril),
which makes this vaccine attractive especially, but not
only, for children. The donor strains are also tempera-
ture sensitive (‘‘cold adapted’’): optimal viral replication
occurs at 25C (the approximate temperature in the
nasal cavity) with virtually no replication at 37C thus
avoiding spread to the lower airways of the vaccinees.
Immunological responses to this vaccine are pronounced
and comprise not only stimulation of systemic but also
of mucosal immunity. Therefore they resemble natural
infection more than any other inﬂuenza vaccines [31].
Importantly, signiﬁcant immune responses can be in-
duced even in young infants if repetitive doses are used
[7].
Eﬃcacy of CAIV-T has been investigated in several
studies in healthy children and adolescents (Table 1). In
a pivotal study where 1602 children 15 to 71 months of
age received one or two doses of CAIV-T 6 to 10 weeks
apart, overall eﬃcacy against culture-conﬁrmed inﬂu-
enza virus infection was 93% (95% CI 88–96) with rates
of 89% and 94% for the one or two-dose schedules,
respectively [3]. Speciﬁcally, after one and two doses,
eﬃcacy against inﬂuenza A/H3N2 was 87% (95% CI:
47–97) and 96% (90%–99%), respectively. Respective
eﬃcacy rates for inﬂuenza virus B were 91% (46%–
99%) and 91% (78%–96%). In the following year, eﬃ-
cacy against an antigenically drifted H3N2 virus type A
was still 86%. Results of this and other studies are
summarised in Table 1. Studies in children and adoles-
cents with underlying chronic illness (e.g. asthma) are
currently being conducted. Of note, concerns have been
expressed that repeated application of CAIV (which, like
other inﬂuenza vaccines needs to be adapted each year)
might lead to an impaired ability of replication due to
induction of an immune response against core antigens
of the master assortant [43]; However, clinical experi-
ence so far has not supported this theoretical concern [3,
12,18].
Tolerability of CAIV-T appears to be good. Mild
upper respiratory tract symptoms such as rhinorrhoea
and nasal congestion have been observed at rates of 10%
above those after placebo on days 2 and 3 after nasal
administration of the vaccine in children [2]. Short-lived
and low-grade fever attributable to vaccine was ob-
served only on day 2 of the ﬁrst dose (6.5% of vaccinees
compared to 1.6% of placebo controls) as was decreased
activity (6.0% versus 2.1%). Sequential annual doses of
CAIV-T in the same cohort were generally well tolerated
with low rates of mild respiratory, gastrointestinal and
systemic symptoms [45]. Data on tolerability of CAIV-T
in children and adolescents with underlying illnesses are
limited and mainly derive from studies in asthmatics or
patients with cystic ﬁbrosis [19, 33,54]. Further studies
are currently being conducted in several European
countries.
Shedding of CAIV-T has been found in nasopha-
ryngeal secretions of vaccinees for up to 12 days [1]. This
has raised concerns about the possibility of vaccine virus
transmission to close contacts; however, evidence so far
indicates that this does not appear to be a frequent
event, if it occurs at all [61]. Further safety consider-
ations with the use of CAIV-T are directed towards the
possibility that ‘‘infection’’ with the vaccine virus might
Table 1 Eﬃcacy Trials with CAIV-T in children and adolescents
Reference Study subjects (n) Age Vaccine eﬃcacy (%) Comments
[44] 192/169 3–18 years A/H3N2; 1 dose: 89%
A/H1N1; 1 dose: 100%
Bivalent vaccine without type B
[18] 182 6–18 months A/H3N2; 1 dose: 65% Eﬃcacy against H1N1 infections
not studied
[3] 1602 15–71 months A/H3N2; 1 dose: 87%; A/H3N2;
2 doses: 96%; B; 1 dose: 91%; B;
2 doses: 91%
Pivotal eﬃcacy trial which led to licensure
of the vaccine in the United States
[36] 600 1–16 years A/H3N2; 1 dose: 68%; A/H1N1;
1 dose: 95%
Study over 5 consecutive years
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pave the way for secondary bacterial infections, genetic
and phenotypic alterations in the CAIV master virus,
and re-assortment of CAIV with inﬂuenza wild type
virus genes in co-infected vaccinees [43]. Experience so
far lends no support for any of these concerns. However,
careful post-licensure surveillance will deﬁnitely be
warranted now that CAIV-T (Flumist) has been licensed
for the ﬁrst time in the United States for individuals 5 to
49 years of age for the inﬂuenza season 2003/2004.
Recently, a killed, nasally applied inﬂuenza vaccine
had been developed using virosomal technology and
Escherichia coli heat-labile toxin as a mucosal adjuvant
and licensed in Switzerland [15]. Unfortunately, several
cases of peripheral facial palsy were reported in vacci-
nees during the ﬁrst season after licensure which lead to
withdrawal of the vaccine from the market (press release
by the Swiss Federal Health Oﬃce, September 14,
2001; http://www.bag.admin.ch/dienste/medien/2001/d/
01091424.htm). An extensive safety study was per-
formed the following year in several countries (unpub-
lished) and resulted in termination of further production
of this vaccine by the manufacturer (press release by
Berna Biotech, June 6, 2002).
Although inactivated inﬂuenza whole-cell, split, sub-
unit, and virosome inﬂuenza vaccines are produced by
use of embryonated hen eggs, their application in chil-
dren with allergy to ingested egg proteins (mainly yolk
proteins, ovalbumin and ovomucoid) in general appears
to be safe [26,63]. CAIV-T is produced using hen’s egg
allantoic ﬂuid. Although this vaccine has not been
studied thoroughly in children with allergy to egg pro-
teins, no indication for hypersensitivity after nasal
administration of the vaccine has been observed so far
[43]. Nevertheless, the usual precautions for possible
anaphylactic reactions should be applied as a routine
measurement when immunising against inﬂuenza.
Considerations on current inﬂuenza immunisation
recommendations
As can be seen in Table 2, there is currently signiﬁcant
heterogeneity with respect to which groups of children
and adolescents are considered to be at increased risk
from inﬂuenza in various European countries. This is
surprising because the direct eﬀects of inﬂuenza vacci-
nation programmes based on a risk group strategy are
obvious: morbidity and mortality can be reduced in those
who have been immunised. However, since these indi-
viduals represent only a small minority of all children and
adolescents, indirect eﬀects in the sense of herd immunity
cannot be achieved with such a strategy. Of note, several
countries emphasise in their national guidelines that
inﬂuenza immunisation should be considered for anyone
with the desire to be protected from inﬂuenza, although
these costs will not be covered by health insurance.
It has been shown that schools are the main source
for spread of inﬂuenza virus at the beginning of each
epidemic [13]. The Japanese experience, where inﬂuenza
immunisation was mandatory for schoolchildren from
1977 to 1987, demonstrated that such an expanded
immunisation programme not only prevents conse-
quences of inﬂuenza (morbidity, absence from school) in
the vaccinees themselves, but also indirectly protected
other vulnerable segments of the population, i.e. the el-
derly and other high risk patients [50]. In my view,
whether such a strategy, primarily aiming at providing
herd immunity, would be acceptable for parents and
physicians is doubtful for most European countries. At
least as long as yearly injections would still be necessary,
it is hard to believe that such a goal could be achieved,
when it is diﬃcult enough to convince parents of high
risk patients about the beneﬁts of inﬂuenza immunisa-
tion. Furthermore, any expanded inﬂuenza immunisa-
tion programme would need to be implemented on a
voluntary basis because signiﬁcant resistance against
mandatory immunisations could be envisioned by parts
of the populations of most if not all European countries
today.
Future challenges for inﬂuenza immunization
Several diﬃcult and not so diﬃcult tasks related to
inﬂuenza immunisation lie ahead of us.
First, and most importantly in my opinion, we need
to better educate the current and the next generation of
physicians about the threats of inﬂuenza and the most
eﬃcient way of prevention, i.e. immunisation. This
educational process should start as early as in medical
school and continue during postgraduate training in
hospitals and continuously thereafter. In this respect,
we recently performed a survey among physicians in
our hospital where we assessed their attitudes towards
immunisation against inﬂuenza [23]. Doubts about
necessity (56%) and eﬃcacy (32%) as well as concerns
about side-eﬀects (24%) were the most frequently sta-
ted reasons by the approximately 50% of colleagues
who had declined inﬂuenza immunisation. This exam-
ple demonstrates existing barriers to inﬂuenza immu-
nisation. Also, the public needs to be educated. Of
importance is the fact that many people are unaware of
the signiﬁcant clinical diﬀerence between a common
cold and ‘‘true’’ inﬂuenza. How can they appraise the
value of the vaccine if they are not aware of the exis-
tence of complications of the disease?
Second, improvement of acceptance of inﬂuenza im-
munisation needs to be achieved in high risk patients.
This goal can only be achieved in close link to the
educational need stated above.
Third, better surveillance of morbidity and potential
long-term sequelae in young infants is required in order
to have a basis for the discussion of the issue of a general
inﬂuenza immunisation strategy. At the same time,
transmission patterns of inﬂuenza between children and
adults should be studied.
Fourth, ways to avoid shortage of vaccine, which
has been encountered recently, should be explored.
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Currently, each dose of vaccine requires one hen’s egg.
Research should focus on the development of cell cul-
ture techniques for inﬂuenza vaccine strain production
to overcome the current production limitations in terms
of vaccine quantities.
Fifth, immunising pregnant women against inﬂuenza
should be evaluated more intensively. This could not
only decrease the risk for complications attributable to
inﬂuenza in pregnant women themselves but would also
potentially protect their infants via transplacental
transfer of speciﬁc IgG antibodies for the ﬁrst few
months of their lives – a period where hospitalisation
rates for inﬂuenza are highest [35].
Finally, the ultimate goal would be the development
of a vaccine with eﬃcacy beyond the next inﬂuenza
season. Naturally, this would require detection of pro-
tective antigens which are not subject to regular muta-
tions (drifts) and thus do not allow the virus to evade
from the host’s speciﬁc immune responses. Progress in
genome sequencing has opened the door to this prom-
ising area of research.
Chemoprophylaxis
In the recent past, the introduction of a new class of
antiviral drugs, the NIs, has supplemented our armament
to ﬁght inﬂuenza [8]. In contrast to Amantadin, which
blocks the ion channels (M2 protein) of inﬂuenza virus
type A (Fig. 1) and has been only available for treatment
of children with inﬂuenza type A but not type B infec-
tions for many years, NI are eﬃcacious against types A
and B. They can be used for treatment and prophylaxis
[48]. They function by interfering selectively with the NA
of inﬂuenza virus types A and B and thus inhibit the
release of new viruses from infected cells (Fig. 4). Use of
NIs may induce resistance in some inﬂuenza virus strains.
However, these resistant strains have been shown to be
defective in virulence and less contagious when compared
to susceptible strains [20].
So far, two NIs have been licensed in Europe and
other parts of the world. Zanamivir (Relenza) is
insuﬃciently resorbed when given orally and therefore
must be administered as a powder by inhalation.
Table 2 Recommendations for inﬂuenza immunisation in children
and adolescents in selected European countries. Data are based on
information obtained from the published immunisation recom-
mendations of Austria (http://www.gesundheit.bmsg.gv.at),
Germany (www.rki.de) and Switzerland and the following collea-
gues and members of the European Society for Paediatric
Infectious Diseases (ESPID) as obtained in June 2003: H. Bogaerts
(Belgium), V. Pellantova (Czech Republic), N. Valerius (Denmark),
K. Zilmer (Estonia), H. Noyhnek (Finland), D. Gendrel and
E.Grimprel (France), G. Syrogiannopoulos andM. Tsolia (Greece),
A.Haraldsson and S. Sigurdardottir (Iceland), S. Knowles (Ireland),
S. Esposito and R.F. Schumacher (Italy), D. Gardovska (Latvia), V.
Usonis (Lithuania), A. Berstad (Norway), A. Neto and L. Varandas
(Portugal), N. Hawash and S. Yakushin (Russia), M. Cizman
(Slovenia), F. Asensi (Spain), H. Heijbel (Sweden), R. de Groot and
J. L. Kimpen (Netherlands), A. Finn and M. Sharland (UK). No
information could be obtained for Bulgaria, Poland, Romania, Slo-
vakia and the former Yugoslavia. ‘‘Yes’’: speciﬁcally indicated;
‘‘No’’: not indicated; ‘‘-’’: no oﬃcial guideline exists
Countries Chronic cardio-
vascular disease
Chronic respiratory
disease
Diabetes
mellitusa
Chronic renal
disease
Immuno-suppressed
patientsb
Long-term acetyl-
salicylate treatment
Austria Yes Yes Yes Yes Yes No
Belgium Yes Yes Yes Yes Yes Yes
Czech Republicc – – – – – –
Denmark No Yes No No No No
Estoniac – – – – – –
Finland Yes Yes Yes Yes Yes Yes
France Yes Yes Yes Yes Yes Yes
Germany Yes Yes Yes Yes Yes No
Greece Yes Yes Yes Yes Yes Yes
Hungaryc – – – – – –
Icelandc – – – – – –
Ireland Yes Yes Yes Yes Yes Yes
Italy Yes Yes Yes Yes Yes Yes
Latviac – – – – – –
Lithuaniac – – – – – –
Norway Yes Yes No No Yes No
Portugal Yes Yes Yes Yes Yes Yes
Russia Yes Yes Yes Yes Yes Yes
Slovenia Yes Yes Yes Yes Yes No
Spain Yes Yes Yes Yes Yes Yes
Sweden Yes Yes Yes Yes Yes No
Switzerland Yes Yes Yes Yes Yes Yes
The Netherlands Yes Yes Yes Yes Yes Yes
United Kingdom Yes Yes Yes Yes Yes No
aExplicitly mentioned or as part of ‘‘metabolic diseases’’ category;
frequently limited to insulin-dependent diabetes mellitus
bExplicitly including HIV-positive patients in some but not all
countries; frequently including patients with haemoglobinopathies
leading to functional asplenia
cDespite lack of oﬃcial guidelines, inﬂuenza immunisations are
performed on individual physicians’ decisions and/or are supported
by national paediatric societies in these countries
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Doses of 5 mg are administered with a special device
called a ‘‘diskhaler’’. In most countries, Zanamivir has
only been licensed for treatment of inﬂuenza in indi-
viduals 12 years of age and older but not for pro-
phylaxis, although its preventive eﬃcacy has been
shown in studies in adults and children older than 5
years [22,34]. In Switzerland, Zanamivir has been li-
censed for treatment (5 years of age onwards) and
prophylaxis (12 years of age onwards) of inﬂuenza for
up to 1 month duration.
In contrast to Zanamivir, Oseltamivir (Tamiﬂu) has
an excellent bioavailability after oral administration as a
capsule or liquid suspension. The dosage is weight
dependent and ranges from 30 to 75 mg. Based on
available eﬃcacy data, Oseltamivir has been licensed for
treatment (1 year of age and older) and prophylaxis
(from 13 years of age onwards) of inﬂuenza infections.
For prevention of inﬂuenza, Oseltamivir can be given
once daily during the inﬂuenza season and its tolerability
has been shown for up to 6 consecutive weeks of
administration. For post-exposure prophylaxis, once
daily use for 7 days is recommended. However, for pre-
vention of inﬂuenza in children and adolescents, the
experience with this drug is limited. In one study, Osel-
tamivir demonstrated an eﬃcacy of 82% when given
once daily for 10 days as post-exposure prophylaxis to
children who had been exposed to a sibling with inﬂuenza
[21]. Probably because of the relatively high costs, clinical
use of NIs is currently limited to a few countries, mainly
Japan, the United States and some in Europe [53].
To my knowledge, the only guidelines in Europe for
the use of NIs in high risk paediatric patients (i.e. those
for whom inﬂuenza immunisation is recommended) have
been developed by the Committee for Infectious Dis-
eases and Vaccines of the German Academy for Paedi-
atrics [11]. They are similar to those formulated by the
United States Advisory Committee on Immunization
Practices [6]. According to the German Committee, the
use of Oseltamivir should be considered for prevention
during epidemics of inﬂuenza under the following cir-
cumstances (note: age dependent licensure restrictions,
which may diﬀer from country to country, should be
observed):
1. If inﬂuenza vaccine has not been administered due to
a contraindication (use for up to 6 weeks)
2. If no inﬂuenza vaccine is available for prophylaxis
(use for up to 6 weeks)
3. If inﬂuenza vaccine has only been administered after
the onset of the epidemic and the period until full
vaccine protection can be assumed is to be covered
(use for 10 to 14 days)
4. If inﬂuenza vaccine has not been administered and
exposure to a household member with suspected or
proven inﬂuenza has occurred (use for 7 days)
5. If the inﬂuenza epidemic is caused by a mutated virus
diﬀerent from the current vaccine strains, irrespective
of the patient’s vaccination status (use for up to 6
weeks)
Conclusions
Inﬂuenza is known to be a frequent cause of respiratory
tract infections in the paediatric age group. Further ef-
forts are still needed to increase the knowledge among
physicians and the public about the signiﬁcant burden of
disease in children and adolescents caused by inﬂuenza
viruses. Moreover, increased educational activities about
the beneﬁts of prevention of inﬂuenza are necessary to
better implement existing immunisation recommenda-
tions which would improve the health of our patients.
These activities should be augmented by innovative re-
search aiming at more eﬃcient manufacturing technol-
ogies and new vaccines with prolonged eﬃcacy. Finally,
antiviral drugs like NIs can reasonably complement but
not substitute our current inﬂuenza immunisation
strategies.
Fig. 4 Infection of respiratory
cells by inﬂuenza virus,
replication and release of new
virus particles. Interference with
release of viruses by NIs
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